TURNING POINT IN
Humacyte is pioneering the development and manufacture of off-the-shelf, universally implantable, immediately available, bioengineered human tissues. The Humacyte Human Acellular Vessel (HAV) is a first-in-class regenerative vascular conduit currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. The platform technology also has the potential to create solutions for complex organ disease, including bioengineered replacement tissues and organs for coronary artery bypass grafts, pediatric heart surgery, and the treatment of Type 1 diabetes.
Humacyte is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at a commercial scale to improve the lives of patients and transform the practice of medicine. Humacyte develops and manufactures acellular tissues to address life- and limb-threatening vascular conditions while focusing on potential future applications for complex organ disease. Located in Durham, N.C., Humacyte announced the intent to go public via a SPAC in February 2021. The company was founded in 2004 by Laura Niklason, MD, Ph.D., a world leader in tissue engineering and the Chief Executive Officer of Humacyte, along with Drs. Juliana Blum and Shannon Dahl.